Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredient
US9388223B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 3, 2013 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Jan 3, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.